TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32747473
Drug: Distance learning
Normalized name: Cistanche tinctoria stem extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distance learning program consisting of 3 program modules with online tutorials, webinars, booster video vignettes, and individualized antibiotic prescribing feedback reports over 11 months.
Study: 33051459
Drug: Leptin treatment
Normalized name: leptin
DrugBank: Leptin (DB05098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leptin treatment
Study: 36443882
Drug: Standard intermittent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intermittent preventive treatment (IPTp) with sulfadoxine-pyrimethamine (SP)
Study: 34100082
Drug: Sequential mixed-nutrient
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential mixed-nutrient meals
Study: 32489146
Drug: letrozole (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: letrozole (2.5 mg daily) and cyclophosphamide (50 mg daily) with Sorafenib (400 mg/bid daily)
Study: 34880372
Drug: 3% gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% gelatin solution (30 ml/kg) in group A (n=21)
Study: 34880372
Drug: 3% gelatin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3% gelatin solution (15 ml/kg) in group B (n=21)
Study: 34880372
Drug: Isotonic multi-electrolyte
Normalized name: MULTI-ELECTROLYTES INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic multi-electrolyte solution in control group C (n=22)
Study: 35289915
Drug: Full dose-intensity
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose-intensity (DI) in FOLFIRINOX group
Study: 35289915
Drug: Full dose-intensity
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose-intensity (DI) in FOLFIRI/nab-paclitaxel group
Study: 35384257
Drug: Topical probiotic-derived
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical probiotic-derived lotion
Study: 36057827
Drug: Placebo tablets
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once per day
Study: 35216547
Drug: Leuprorelin (3.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Leuprorelin (3.75 mg s.c. monthly for the first 3 months followed by 11.25 mg s.c. every 3 months)
Study: 32692358
Drug: (R)-α-lipoic acid
Normalized name: Lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: (R)-α-lipoic acid (R-LA; 600 mg/d)
Study: 33231701
Drug: 0.2 μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/day fluocinolone acetonide (FAc) intravitreal implant
Study: 33157330
Drug: Adjunctive photodynamic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive photodynamic therapy (aPDT)
Study: 33157330
Drug: Adjunctive antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive antibiotic gel therapy (aAGT) (metronidazole 400 mg and amoxicillin 500 mg)
Study: 32928014
Drug: Dexamethasone (2mls,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2mls, 8 mg) intravenously
Study: 33382378
Drug: Website and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website and personalized diet and exercise prescription (level 2)
Study: 33382378
Drug: Website, personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website, personalized prescription, Fitbit, and text messages (level 3)
Study: 33382378
Drug: Website, personalized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Website, personalized prescription, Fitbit, text messages, and 2 phone calls (level 4)
Study: 34418964
Drug: Medication plans
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Medication plans and discussions with GPs
Study: 34418964
Drug: Personal experiences
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personal experiences with medications
Study: 35124615
Drug: Digital group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital group (CAD/CAM digital implant guide)
Study: 33486138
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (active control group, n2 = 20)
Study: 35267967
Drug: Symbiotic nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic nutritional supplement (daily mixture of symbiotics, omega-3/6 fatty acids, and amino acids)
Study: 33858395
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as Usual Control (CTRL)
Study: 34803132
Drug: Monthly anti-VEGF
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Monthly anti-VEGF injections
Study: 39675824
Drug: Empagliflozin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin (10 mg/day)
Study: 32990938
Drug: Intravenous patient-controlled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous patient-controlled analgesia (PCA) with fentanyl
Study: 36335783
Drug: Regorafenib 160
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 160 mg QD (arm A)
Study: 32069126
Drug: Etonogestrel-releasing subdermal
Normalized name: etonogestrel
DrugBank: Etonogestrel (DB00294)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Etonogestrel-releasing subdermal implant
Study: 32069126
Drug: 52-mg levonorgestrel-releasing
Normalized name: levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 52-mg levonorgestrel-releasing intrauterine system
Study: 36371675
Drug: Inhalation anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation anesthesia (sevoflurane maintenance)
Study: 35412685
Drug: N. sativa
Approvals — FDA: no, EMA: no, PMDA: no
Description: N. sativa oil (two capsules of 500 mg)
Study: 35412685
Drug: Placebo (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (two capsules of 500 mg mineral oil)
Study: 34314574
Drug: Rivaroxaban (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (10 mg/day for creatinine clearance ≥50 ml/min; 7.5 mg/day for ≥30-<50 ml/min)
Study: 39264503
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of rosuvastatin
Study: 32629662
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba extract tablets
Study: 32930627
Drug: TCHMC 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCHMC 200 g per day
Study: 32930627
Drug: TCHMC 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TCHMC 300 g per day
Study: 32930627
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 g TCHMC per day)
Study: 34244277
Drug: Guided self-help
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Guided self-help intervention (EG) based on Acceptance and Commitment Therapy (ACT), comprising an introduction and seven modules (one module per week, processing time about 45-60 min).
Study: 32184007
Drug: General anesthesia
Normalized name: Ethers for general anesthesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: General anesthesia alone (G group)
Study: 33615395
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 0.15 mg Se/kg (NS-Gly)
Study: 33615395
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 0.60 mg Se/kg (NS-Gly)
Study: 33615395
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 0.30 mg Se/kg (Na2SeO3)
Study: 33615395
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet (control, 0.13 mg Se/kg)
Study: 33615395
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 0.30 mg Se/kg (NS-Gly)
Study: 33615395
Drug: Basal diet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal diet + 0.45 mg Se/kg (NS-Gly)
Study: 33142505
Drug: Natural astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural astaxanthin (ASTA) 25 mg/kg
Study: 33142505
Drug: Natural astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural astaxanthin (ASTA) 50 mg/kg
Study: 33142505
Drug: Natural astaxanthin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural astaxanthin (ASTA) 100 mg/kg
Study: 33142505
Drug: Control (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (0 mg/kg ASTA)
Study: 36129031
Drug: Methohexital (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methohexital (0.5 mg/kg)
Study: 32557166
Drug: Ultra-low dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low dose CT (ULDCT)
Study: 35221758
Drug: Dexmedetomidine 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine 1.0 μg/kg
Study: 32759621
Drug: Rectal ulcers
Normalized name: adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rectal ulcers >2 cm
Study: 32759621
Drug: Deep rectal
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep rectal ulcers >2 cm
Study: 33722073
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus fluoxetine
Study: 33722073
Drug: Cognitive behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioural therapy plus placebo
Study: 34461078
Drug: Low-molecular-weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight heparin (enoxaparin; 40 mg subcutaneously)
Study: 34461078
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no low-molecular-weight heparin)
Study: 32049831
Drug: pyridostigmine 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: pyridostigmine 0.2 mg/kg plus glycopyrrolate 0.01 mg/kg
Study: 33296560
Drug: Paclitaxel-coated devices
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-coated devices (drug-coated-device group)
Study: 39215323
Drug: Dexamethasone (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (8 mg)
Study: 32812663
Drug: Cream containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cream containing niosomes loaded with 1% w/v purple glutinous rice extract
Study: 34166648
Drug: 52 mg
Normalized name: papain 52 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 52 mg levonorgestrel intrauterine system (IUS)
Study: 35027169
Drug: High-Flow Nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Flow Nasal Oxygen (70 L min−1)
Study: 35027169
Drug: Facemask Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facemask Oxygen (15 L min−1)
Study: 33688840
Drug: Online mindfulness-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Online mindfulness-based cognitive behavioral therapy (CBT-M) combined with standard psychiatric care (n=22)
Study: 33944622
Drug: Atomoxetine (ATX)
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atomoxetine (ATX) at a starting dose of 0.5 mg/kg/day, titrated to 1.2 mg/kg/day
Study: 34744060
Drug: Mg-Ca alloy
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Allay]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-Ca alloy scaffold
Study: 34744060
Drug: Mg-Sr alloy
Normalized name: acetaminophen / hydrocodone bitartrate Oral Capsule [Allay]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mg-Sr alloy scaffold
Study: 34158437
Drug: Scaling and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Scaling and Root Planing and Punica granatum gel
Study: 34647849
Drug: chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: chemotherapy alone
Study: 35177053
Drug: Dapagliflozin as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin as an add-on therapy to standard of care (SoC)
Study: 33961534
Drug: Red light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red light LED therapy 2–3 times/week for 6 weeks
Study: 33961534
Drug: Red light
Normalized name: kaolin light
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red light LED therapy
Study: 33293656
Drug: Highly Active
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Highly Active Antiretroviral Treatment (HAART)
Study: 33261620
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of all beneficial strategies
Study: 35085318
Drug: Ultrasound-guided peripheral
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided peripheral intravenous catheter (UL PIVC)
Study: 35085318
Drug: Vesicant doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vesicant doses (≥ 3 vs 0)
Study: 32756843
Drug: Urea with
Normalized name: DermacinRx Urea with Salicylic Acid 39.5%-2% Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Urea with NBPT urease inhibitor
Study: 32756843
Drug: Nitrogen treatments
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrogen treatments
Study: 34928698
Drug: Bamlanivimab (7000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bamlanivimab (7000 mg)
Study: 34547193
Drug: Mirabegron 25
Normalized name: mirabegron 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron 25 mg daily
Study: 32930113
Drug: Kanglaite (KLT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kanglaite (KLT) injection combined with gefitinib
Study: 32230721
Drug: Robuvit® (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robuvit® (300 mg/day) for 4 weeks
Study: 34235560
Drug: Zilver PTX
Normalized name: PTX-100
DrugBank: PTX-100 (DB18125)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilver PTX drug-coated stent
Study: 39512761
Drug: Quadrivalent recombinant
Normalized name: INFLUENZA VACCINE,QUADRIVALENT RECOMBINANT (PF),SYRINGE,0.5ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quadrivalent recombinant influenza vaccine (RIV4)
Study: 33417279
Drug: 2‐IOD (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2‐IOD (two implants in the canine regions bilaterally)
Study: 32861144
Drug: HAART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART treatment for 48 weeks in low microbial translocation (MT) group
Study: 32861144
Drug: HAART treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAART treatment for 48 weeks in high microbial translocation (MT) group
Study: 35513910
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic (Vivomixx®) 4.4 g/day for 4 weeks
Study: 35513910
Drug: Non-probiotic milk-powder
Normalized name: Milk powder
DrugBank: Skim milk (DB15546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-probiotic milk-powder placebo 4.4 g/day for 4 weeks
Study: 32469166
Drug: Cyclosporine A
Normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine A (CsA) treatment
Study: 33890158
Drug: Concurrent training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent training (PAR)
Study: 36399673
Drug: Rivaroxaban 10
Normalized name: rivaroxaban 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 10 mg once daily for three weeks
Study: 32027842
Drug: m102.4 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: m102.4 (1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg)
Study: 32027842
Drug: m102.4 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: m102.4 (20 mg/kg, two infusions 72 hours apart)
Study: 32924183
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) training for PHNs
Study: 35149322
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with prescription OUD
Study: 32500344
Drug: Adjuvant transcatheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant transcatheter arterial infusion therapy (TAI)
Study: 34078808
Drug: Limited-point plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Limited-point plasma concentration analysis of CYP substrates in a cocktail drug
Study: 35728621
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy
Study: 35982449
Drug: Margarine without
Normalized name: MARGARINE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Margarine without TFA (wTFA control group with 0.4 g TFA per 100 g margarine)
Study: 35982449
Drug: Butter with
Normalized name: Suave Cocoa Butter with Shea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Butter with rTFA (rTFA group with 6.3 g TFA per 100 g butter)
Study: 32702252
Drug: HEA-enriched Cordyceps
Normalized name: CORDYCEPS SINENSIS
DrugBank: Ophiocordyceps sinensis (DB19288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HEA-enriched Cordyceps cicadae mycelium (1.05 g granules once a day for 3 months)
Study: 35372614
Drug: Sexual health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sexual health counseling based on cognitive-behavioral therapy (CBT), 8 sessions of 90 minutes each
Study: 33858620
Drug: Tocilizumab (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tocilizumab (280 mg single infusion)
Study: 32731960
Drug: Cryotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryotherapy with mobilization (CM) twice per week for 5 weeks
Study: 32046656
Drug: Stratified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified care using the Keele STarT MSK development tool for risk-stratification and matched treatment options for low-, medium-, and high-risk patients.
Study: 32046656
Drug: Stratified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified care using matched treatment options.
Study: 32046656
Drug: Stratified care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stratified care using the Keele STarT MSK tool and matched treatment options.
Study: 36468569
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg daily for 2 weeks)
Study: 36468569
Drug: Diclofenac (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac (50 mg three times daily for 2 weeks)
Study: 36468569
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of omeprazole and diclofenac (for 2 weeks)
Study: 34057698
Drug: CPP-ACP cream
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CPP-ACP cream (daily single application)
Study: 34122682
Drug: Vitamin C
Normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin C and Vitamin E combination
Study: 32489082
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese medicine
Study: 32489082
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese medicine (tablets and granules)
Study: 32489082
Drug: Oral Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Chinese medicine (decoction and oral liquids)
Study: 32489082
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of oral Chinese medicine and Western medicine
Study: 36201354
Drug: ATI-2173 10
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-2173 10 mg
Study: 36201354
Drug: ATI-2173 25
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-2173 25 mg
Study: 36201354
Drug: ATI-2173 50
Normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATI-2173 50 mg
Study: 34727277
Drug: Pre-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment group
Study: 34727277
Drug: Post-treatment group
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Post-treatment group
Study: 34264503
Drug: FKB238 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: FKB238 15 mg/kg
Study: 37945413
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion
Study: 32992190
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) beyond 90 days (on clopidogrel)
Study: 35303909
Drug: bamlanivimab (700
Approvals — FDA: no, EMA: no, PMDA: no
Description: bamlanivimab (700 mg, 2800 mg, or 7000 mg)
Study: 32162239
Drug: Licorice flavonoid
Normalized name: Licorice Flavanoid Oil
DrugBank: Glycyrrhiza glabra (DB14312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Licorice flavonoid oil (LFO) supplementation (300 mg daily for 16 weeks)
Study: 36803892
Drug: Epidural corticosteroid
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural corticosteroid injection
Study: 33851448
Drug: 80 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 80 mg/day nano-curcumin
Study: 32492712
Drug: D-dimer >2,500
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-dimer >2,500 ng/mL
Study: 33555982
Drug: Standard insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard insulin pump therapy
Study: 33559438
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at 5-6 local acupoints and 3-4 distal acupoints, retained for 30 min, three times a week for 8 weeks.
Study: 33559438
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture treatment with shallow needling technique at non-acupoint, retained for 30 min, three times a week for 8 weeks.
Study: 32279619
Drug: Endovascular treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endovascular treatment for acute ischemic stroke
Study: 34916068
Drug: Sertraline (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline (n = 106) for 8 weeks
Study: 34916068
Drug: Bupropion (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (n = 37) for 8 weeks after sertraline nonresponse
Study: 32664244
Drug: PATCH self-assessment
Approvals — FDA: no, EMA: no, PMDA: no
Description: PATCH self-assessment
Study: 35579104
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care tablet containing kiwifruit powder (intervention II)